Santen Expands Into Surgical Devices and Publishes Real-World Evidence in Dry Eye Disease


In addition to launching a new monofocal, hydrophobic IOL, xact Mono-EDoF, a panel of experts including Ike K. Ahmed, reviewed current surgical techniques and introduced Santen’s Preserflo MicroShunt device at the recent ESCRS meeting in Paris.

Preserflo MicroShunt is a surgical device designed in collaboration with ophthalmologists that helps to drain eye fluid and reduce IOP for patients suffering from primary open-angle glaucoma (POAG).

“With the launch of our new, pioneering intraocular lens and continued roll-out for the innovative Preserflo MicroShunt, Santen’s position as a specialist and leader in ophthalmology is further strengthened,” Luis Iglesias, Head of Santen EMEA, said in a company news release. “In addition to our surgical devices offering, we continue to invest in our pharmaceutical portfolio including our ongoing commitment to real-world evidence to support the use of our medicines in a clinical setting.”

The 24-week results of PERSPECTIVE, an ongoing 12 month, non-interventional, multicenter, European, prospective study were presented at ESCRS 2019 as a poster. The study evaluated the effectiveness, tolerability and safety of cyclosporine A (CsA) 0.1% eye drop emulsion, marketed as Ikervis, in controlling severe keratitis and other parameters including improvement of symptoms, in adult dry eye patients, who had previously failed to respond to artificial tear treatments. The interim analysis data demonstrated that CsA 0.1% eye drop emulsion provides an effective, well tolerated and safe treatment at Week 24, compared with baseline, in adults with dry eye disease (DED) and severe keratitis.

Key findings include:

  • CsA 0.1% eye drop emulsion provided significant improvements in corneal fluorescein staining (CFS) grade at Week 24 (77.4%)
  • Statistically significant improvements were also demonstrated at Week 24, from baseline, concerning tear break-up time (TBUT) as well as objective and subjective measures
  • Most physicians regarded CsA 0.1% eye drop emulsion to be more effective than previous treatments. Both physicians and patients rated the tolerability of treatment highly
  • Most treatment-related adverse events (TRAEs) were localized at the administration site and 67.7% were recovered without issue


Related Content